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The lysosomal degradation of glucosylceramide requires the hydrolase, glucosylceramide-/3-glucosidase and a sphingolipid activator protein 
(Gaucher factor, SAP-Z, saposin C). Genetic defects in either of these lysosomal proteins cause phenotypically similar disorders in man, the Gaucher 
disease. SAP-2 originates from a gene which generates a mRNA that codes for four homologous proteins. In a patient with an immunologicnii~ 
proven SAP-2 deficiency a GiiH + T transversion (counted from A of the initiation codon ATG) was found in the mRNA of the SAP-2 precursor 
which results in the substitution of Phe for Cys3*’ in the mature SAP-2. The rest of the coding sequence remained entirely normal. 
SAP-2 deficiency; Gaucher disease 
1. INTRODUCTION 
The physiological degradation of glycosphingolipids 
with short oligosaccharide chains is catalyzed by lyso- 
somal exohydrolases in the presence of small, heat- 
stable lysosomal glycoproteins, so called sphingolipid 
activator proteins (SAPS) [l]. Their physiological sig- 
nificance is demonstrated by fatal lipid storage diseases 
caused by deficiencies of these activator proteins [ 1,2]. 
So far, human diseases have been described with defects 
in three different activator proteins: AI3 variant of 
GM2 gangliosidosis caused by a deficiency of the GM2 
activator protein (SAP-3) [33, a variant of metachroma- 
tic leukodystrophy due to a defect in SAP-1 [4], a 
variant of Gaucher disease with an immunologically 
proven deficiency of SAP-2 [5] and a patient with pleio- 
trophic lipid accumuIation and the immunologically 
demonstrated absence of two activator proteins, SAP-l 
and SAP-2 [6]. 
SAP-l and SAP-2 are derived from the same gene 
that generates an mRNA coding for four homologous 
proteins [7-g]. SAP- 1 is the second and SAP-2 the third 
domain of the four homologous proteins generated 
from the precursor protein. 
Up to now three different mutations in the coding 
region of the SAP-l domain have been identified in pa- 
tients with atypical forms of metachromatic leuko- 
dystrophy [lo-131. 
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In this report we describe for the first time a mutation 
in the coding region of the SAP-2 domain (saposin C) 
in a patient with an atypical form of Gaucher’s disease 
that was described by Christomanou et al. [5]. 
2. MATERIALS AND METHODS 
2.1. RNA isolation and characterization 
Total RNA was isolated from cultured skin fibroblasts by using the 
guanidine isothiocyanate/cesium chloride procedure [14]. Poly(A) 
RNA was selected using Type 7 oligo(dT) cellulose (Pharmacia). 
Northern transfer of electrophoresed mRNA onto nitrocellulose 
membrane was done according to Ausubel et al. [IS]. 
2.2. Isolation of genornic DNA 
Genomic DNA was isolated from cultured fibroblasts according to 
a method of Ausubel et al. [IS]. 
2.3. PCR anlplification of cDNA and genomic DNA 
First strand cDNA was synthesized from total RNA by specific 
oligonuclcotide primers, using the kit purchased from Promega ac- 
cording to the manufacturer’s instructions. The entire protein coding 
sequence including 33 bases of 5 ‘-untranslated region and 77 bases of 
3’-untranslated region (nucleotides -33 to 1661) was amplified by 
overlapping PCR [16], using a series of synthetic I&tl-mer oligo- 
nucleotide primers (Fig. 1). The genomic fragment containing the 
mutation [1017-1201 (numbering from the A of the ATG initiation 
codon)] was amplified by PCR based on the known exon/intron 
structure of the gene [17]. 
2.4. Direcl seyuwcing of the DNA 
The amplified DNA was purified by centrifuge-driven dialysis on a 
Centricon 30 microconcentrator (Amicon). Direcr sequencing of the 
PCR-products was done by employing a Sequenasc kit (United States 
Biochemical Co.) and the method of Wang ct al. [18]. A total of 9 
synthetic IS-21.mer oligonucleotidc scqucncing primers wcrc used 
(Fig, I). Scqucncing of both strands was done for confirmation. 
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Fig. 1. Organization of the full length eDNA of the precursor protein foz SAP-I and SAP-2 and location of the PCR and sequencing primers• 
The four white regions represent the four protein domains (A = saposin A, B = SAP-I (saposin B), C -- SAP-2 (saposin C), D = component 
C (saposin D)). The primer combinations u ed for amplification are shown above the bars representing the PCR-products of eDNA (a) and genomic 
DNA (b). 
3. RESULTS AND DISCUSSION 
We report on a Caucasian female patient with an 
atypical form of Gaucher's disease who suffered from 
a severe glucosylceramide accumulation i the spleen 
without having a deficiency of glucosylceramide-D. 
glucosidase [19]. Immunological studies of 
Christomanou et al. [5] gave evidence for the lack of the 
glucosylceramide activator protein (Gaucher factor, 
SAP-2). 
A preliminary Northern blotting experiment on the 
poly(A) RNA fraction showed presence of the SAP-2 
precursor mRNA of apparently normal size in the pa- 
tient's cultivated fibroblasts, indicating the feasibility 
of approaching the mutation from cDNA analysis (data 
not shown). The entire protein coding sequence of the 
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Fig, 2, Sequence of a portion of the SAP-2 eDNA coding strand. 
Direct sequence data of  PCR products were obtained (A) from the pa. 
tient's mRNA (the O -'. T mutation is indicated by an arrow) and (B) 
from a control mRNA, 
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Fig. 3, Part of the genomic sequence of the patient's SAP-2 precursor, 
There are two bands (G and T) at the same level of the aut0radiogram 
indicating that the index case is heterozygous for the n~utadon, 
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patient’s cDNA was normal except for a single nucleo- 
tide change at position 1154 (numbering from A of the 
ATG initiation codon) from the normal G to T (Fig. 2). 
T!:is transversion was observed in 6 batches of cDNA, 
each prepared by amplification of different batches of 
cellular RNA. The transversion results in a substitution 
of Phe for normal Cys in the mature SAP-2. Amplifica- 
tion and sequencing of the genomic DNA around the 
mutation, however, yielded the mutated sequence as 
well as the normai sequence (Fig. 3). These findings sug- 
gest that the patient is a compound heterozygote with 
the identified mutation in one allele and another as yet 
unidentified mutation in the other allele, which might 
be of an mRNA negative type. 
Each of the four homologous proteins generated 
from the SAP-2 precursor contains six cysteine residues 
at strictly conserved positions [7-91. The exchange of 
the fifth Cys residue in the mutant SAP-2 by Phe may 
result in a failure to form normal disulphide bonds. The 
resultant disruption of the normal three-dimensional 
structure is likely to make the mutant SAP-2 (Gaucher 
factor) unstable, consistent with the lack of cross- 
reactive material in the patient’s tissues [5]. 
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